Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 5/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30194507 | 1.00 | SGMS2 (0.59) | SGMS2NPC1HTTGAAFOLH1 | |
| SCHEMBL20819560 | 0.86 | NPC1 (0.53) | SGMS2NPC1HTTGAAFOLH1 | |
| SCHEMBL4481452 | 0.85 | FFAR4 (0.51) | SGMS2NPC1FOLH1L3MBTL1LMNA | |
| SCHEMBL3679181 | 0.85 | SGMS2 (0.60) | SGMS2NPC1HTTGAAFOLH1 | |
| SCHEMBL4473413 | 0.84 | MAOB (0.61) | NPC1FOLH1MEN1KMT2ALMNA | |
| SCHEMBL14339650 | 0.83 | SGMS2 (0.59) | SGMS2NPC1HTTGAAFOLH1 | |
| SCHEMBL4431127 | 0.83 | SGMS2 (0.59) | SGMS2NPC1HTTGAAPARP1 | |
| SCHEMBL6243854 | 0.83 | NPC1 (0.64) | SGMS2NPC1HTTGAAPARP1 | |
| SCHEMBL19156329 | 0.83 | SGMS2 (0.59) | SGMS2NPC1HTTGAAFOLH1 | |
| SCHEMBL4944383 | 0.83 | NPC1 (0.60) | SGMS2NPC1HTTGAAFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3672582-B1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS SINAI MEDICAL CENTER (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260015316-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2026-01-15 | — | — | US | disclosed |
| US-12421185-B2 | Compositions and methods for treating cancer | CEDARS-SINAI MEDICAL CENTER (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250145598-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2025-05-08 | — | — | US | disclosed |
| US-20250064945-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2025-02-27 | — | — | US | disclosed |
| EP-4436965-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-4387617-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | The Regents of the University of California (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2023096987-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023096987-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023023156-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-23 | — | — | WO | disclosed |
| US-5877193-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0882707-A1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0819681-A2 | N-(4-Aryl-thiazol-2-yl)-sulfonamides and their use | F. HOFFMANN-LA ROCHE AG (CH) | 1998-01-21 | — | — | EP | disclosed |
| EP-0647632-A1 | NOVEL BENZODIAZEPINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1995-04-12 | — | — | EP | disclosed |
| EP-0428423-A2 | Aryloxy alkyl benzenes, processes for their preparation and pharmaceutical compositions containing them | LIPHA S.A. (FR) | 1991-05-22 | — | — | EP | disclosed |
| EP-0037062-B1 | SUBSTITUTED 3-ARYL-2-CYCLOALKENE-1-ONES, PROCESS FOR THEIR PREPARATION AND THEIR PARMACEUTICAL USE | Beiersdorf Aktiengesellschaft (DE) | 1984-10-17 | — | — | EP | disclosed |
| US-4401831-A | ADRENOLYTIC AND HYPOTENSIVE AGENTS | BEIERSDORF AKTIENGESELLSCHAFT (DE) | 1983-08-30 | — | — | US | disclosed |
| US-4358460-A | HYPOTENSIVE, ANTIARRHYTHMIA, ANGINA PECTORIS | BEIERSDORF AKTIENGESELLSCHAFT (DE) | 1982-11-09 | — | — | US | disclosed |
| EP-0037062-A2 | Substituted 3-aryl-2-cycloalkene-1-ones, process for their preparation and their parmaceutical use | Beiersdorf Aktiengesellschaft (DE) | 1981-10-07 | — | — | EP | disclosed |
| US-4265903-A | HYPOTENSIVE, ADRENOLYTIC | BEIERSDORF AKTIENGESELLSCHAFT (DE) | 1981-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145598-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | ASAH2, ASAH1, ACER2 | SGMS2 225/4885NPC1 340/4885HTT 4119/4885 |
| US-12421185-B2 | Compositions and methods for treating cancer | TSG101, RNASE1, TP53 | SGMS2 416/4885NPC1 638/4885HTT 2878/4885 |
| US-20250064945-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | SGMS2 3508/4885NPC1 2270/4885HTT 640/4885 |
| US-20260015316-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | GLI1, RCC2, BRCA1 | SGMS2 1600/4885NPC1 356/4885HTT 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.